• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Drug reduces inflammation in stroke patients

Bioengineer by Bioengineer
March 26, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An anti-inflammatory drug given to patients in the early stages of a stroke has been shown by researchers at The University of Manchester and Salford Royal NHS Foundation Trust to reduce harmful inflammation.

The drug, Kineret©, licenced for treating rheumatoid arthritis, was given as a small injection just under the skin without giving the patients any identifiable adverse reactions.

It is one of biologic agents transforming treatment in a range of illnesses.

The protein Interleukin-1 (IL-1) is part of the body's defences and naturally produced to combat a range of illnesses.

However, scientists at the University of Manchester have previously shown IL-1 increases inflammation and brain injury following a stroke.

Kineret works by blocking the actions of IL-1 which is released into the body following injury caused by a stroke.

The researchers, who have published their findings in the journal Stroke, cannot say for sure at this stage how the reduction in inflammation will impact on clinical outcomes.

The study, funded by the Stroke Association, follows earlier research that shows the drug given as an intravenous therapy reduces inflammation in stroke and sub arachnoid haemorrhage patients.

A stroke occurs when poor blood flow to the brain results in cell death. There are two main types of stroke: ischemic, caused by lack of blood flow, and haemorrhagic, caused by bleeding in the brain.

Stroke is the most common cause of disability in adults and a leading cause of death worldwide.

The Manchester study — a double blind trial where Kineret was tested against placebo — looked at ischemic strokes only.

The 80 Participants in the study -carried out at Salford's Greater Manchester Stroke Centre at Salford Royal- were given 6 doses of the drug or placebo over three days. The first dose was given within 6 hours after the onset of the stroke symptoms.

Inflammatory markers were measured in the blood before treatment began and during study treatment.

Professor Craig Smith from The University of Manchester is also a stroke physician at Salford Royal.

He said: "Though Strokes affect different people in different ways, for many people they have a devastating effect on their long-term health and wellbeing.

"Excessive inflammation after a stroke is known to be harmful and predicts a worse outcome in patients."

"We have shown that Kineret injections, started within six hours of stroke onset significantly reduces levels of inflammation in patients."

Hilary Reynolds, Executive Director of Strategy & Research at the Stroke Association said: "This study builds on evidence that IL-1Ra (Kineret) helps to reduce inflammation and brain damage in a wide range of stroke patients soon after a stroke. The drug can be given quickly, via injection or via a drip. This means that it can be used in different settings, for example, it could potentially be given in ambulances on the way to hospital. The brain loses around 2 million brain cells every minute during a stroke, so this could provide a major step forward in fast and effective treatment of stroke.

"The research has not yet proven that this drug can reduce patient disability after stroke. However, if further trials are successful, we hope it could vastly improve outcomes and quality of life for people who have had a stroke."

Further research is needed to see whether Kineret is an effective treatment for ischemic stroke and whether it can be given alongside current treatments such as clot-busting drugs (thrombolysis).

The same research team have shown that Kineret reduces inflammation and is safe in patients with bleeding around the brain, a condition known as subarachnoid haemorrhage.

To definitively test if Kineret improves patient outcomes in subarachnoid haemorrhage, a national trial of Kineret in 1000 patients, funded by the Medical Research Council and National Institute for Health Research, will start in 2018.

And another trial in 80 patients with stroke caused bleeding in the brain, known as intracerebral haemorrhage, will also start in 2018. It is funded by the National Institute for Health Research.

That trial will test if markers of inflammation are reduced by Kineret and test safety in intracerebral haemorrhage.

###

NOTES FOR EDITORS

Professor Smith is available for comment.

The paper, subcutaneous interleukin-1 receptor antagonist in ischemic stroke : a randomized controlled phase 2 trial is published in Stroke and is available

For media enquiries contact:

Mike Addelman
Media Relations Officer
Faculty of Biology, Medicine and Health
University of Manchester
0161-275-2111
07717-881567
[email protected]

Kineret is a trademark of Swedish Orphan Biovitrum AB (publ).

Media Contact

[email protected]
[email protected]
0044-077-178-81567
@UoMNews

http://www.manchester.ac.uk

http://stroke.ahajournals.org/content/early/2018/03/21/STROKEAHA.118.020750

Share12Tweet7Share2ShareShareShare1

Related Posts

Celiac Disease Microbiome and Metabolomics in Chinese Populations

September 1, 2025

Collaborative Mental Health Interventions for Vulnerable Groups

September 1, 2025

Ixekizumab Enhances Quality of Life in Axial Spondyloarthritis

September 1, 2025

Cryo-EM Reveals RAF Autoinhibition and Activation Structures

September 1, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    153 shares
    Share 61 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    143 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Do people and monkeys see colors the same way?

    112 shares
    Share 45 Tweet 28

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Celiac Disease Microbiome and Metabolomics in Chinese Populations

Collaborative Mental Health Interventions for Vulnerable Groups

Chain Recognition Advances Head–Tail Carboboration of Alkenes

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.